Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 25c, provides guidance

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $0.07, $0.25 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $81.8 million versus the consensus estimate of $76.21 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2025 EPS of ($0.35), versus the consensus of ($0.55). Fulgent Genetics, Inc. sees FY2025 revenue of $320 million, versus the consensus of $310.7 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary